Getty Images Pharmaceutical company Arrakis Therapeutics has raised $ $100m m to develop targeted RNA therapies. The Nextech Invest and venBio Partners-led series B funding was also backed by new investors Omega Funds , HBM Healthcare , GV, WuXi AppTec Venture and Alexandria Venture Investments , along with existing backers including Canaan Partners , HBM Healthcare , Pfizer Ventures , Celgene , Osage University Partners and Henri Termeer. Arrakis said it would use the funding to bring one of its Advent Life Sciences therapies to clinical development and had a focus on oncology and other diseases. The company has $100m of funding.
Pharmaceutical company Arrakis Therapeutics has raised $ $100m m to develop targeted RNA therapies. The Nextech Invest and venBio Partners-led series B funding was also backed by new investors Omega Funds , HBM Healthcare , GV, WuXi AppTec Venture and Alexandria Venture Investments , along with existing backers including Canaan Partners , HBM Healthcare , Pfizer Ventures , Celgene , Osage University Partners and Henri Termeer. Arrakis said it would use the funding to bring one of its Advent Life Sciences therapies to clinical development and had a focus on oncology and other diseases. The company has $100m of funding.